Sorafenib N-oxide

Sorafenib N-Oxide is an active metabolite of Sorafenib and belongs to the class of organic compounds known as diarylethers. Sorafenib is a derivative of niacinamide and phenylurea, primarily known for inhibiting several intracellular and cell surface kinases that are crucial to angiogenesis, including RAF kinases and VEGF receptors. Research indicates that Sorafenib N-Oxide also effectively inhibits FLT3 with internal tandem duplication (ITD) mutations, which helps block the proliferation of MV4-11 acute myeloid leukemia (AML) cells that express FLT3-ITD. Notably, it is selective for AML cell lines with FLT3-ITD mutations, differentiating it from cell lines with the wild-type FLT3. In addition, Sorafenib N-Oxide functions as a linear-mixed inhibitor of the CYP3A4 enzyme, with a Ki value of 15 µM in human liver microsomes. This inhibitory action impacts drug metabolism through the cytochrome P450 (CYP) pathway, specifically CYP3A4, which plays a key role in processing various medications. Due to its selective inhibition and efficacy, Sorafenib N-Oxide is considered a promising candidate for cancer treatment, particularly in the therapeutic management of AML.

Sorafenib N-oxide finds application in metabolomics, biochemical and life science related research.

Versatile and adaptable for wide variety of research and metabolomics applications.